Alto Neuroscience
Founded Year
2019Stage
PIPE | IPOTotal Raised
$180.17MMarket Cap
0.44BStock Price
14.19Revenue
$0000About Alto Neuroscience
Alto Neuroscience focuses on developing medicines within the psychiatric treatment domain. The company has a Precision Psychiatry Platform that uses biomarkers to select drug candidates for neuropsychiatric conditions like major depressive disorder, bipolar depression, and schizophrenia. This platform intends to identify suitable patients for specific treatments by utilizing neurobiological insights and AI-derived brain biomarkers. It was founded in 2019 and is based in Mountain View, California.
Loading...
Loading...
Research containing Alto Neuroscience
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Alto Neuroscience in 2 CB Insights research briefs, most recently on Jul 3, 2025.
Expert Collections containing Alto Neuroscience
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Alto Neuroscience is included in 4 Expert Collections, including Digital Health.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Mental Health Tech
791 items
This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.
Artificial Intelligence (AI)
20,629 items
Alto Neuroscience Patents
Alto Neuroscience has filed 16 patents.
The 3 most popular patent topics include:
- antidepressants
- depression (psychology)
- psychiatric diagnosis
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/21/2024 | 2/25/2025 | Psychiatric diagnosis, Piperazines, Antidepressants, Depression (psychology), Abnormal psychology | Grant |
Application Date | 5/21/2024 |
|---|---|
Grant Date | 2/25/2025 |
Title | |
Related Topics | Psychiatric diagnosis, Piperazines, Antidepressants, Depression (psychology), Abnormal psychology |
Status | Grant |
Latest Alto Neuroscience News
Oct 28, 2025
for neuropsychiatric disorders, today announced that members of the Company's management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 10:00-10:30 AM ET Location: New York, New York Jefferies London Healthcare Conference, November 17-20, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date & Time: Monday, November 17 at 3:30-3:55 PM GMT Location: London, UK Available presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto's website and a replay will be available following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, and schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X Availability of Information on Alto's Website Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website. View source version on businesswire.com: https://www.businesswire.com/news/home/20251028146760/en/ Contacts Investor Contact: Nick Smith investors@altoneuroscience.com Recent Quotes View More Symbol Price Change (%)
Alto Neuroscience Frequently Asked Questions (FAQ)
When was Alto Neuroscience founded?
Alto Neuroscience was founded in 2019.
Where is Alto Neuroscience's headquarters?
Alto Neuroscience's headquarters is located at 650 Castro Street, Mountain View.
What is Alto Neuroscience's latest funding round?
Alto Neuroscience's latest funding round is PIPE.
How much did Alto Neuroscience raise?
Alto Neuroscience raised a total of $180.17M.
Who are the investors of Alto Neuroscience?
Investors of Alto Neuroscience include Commodore Capital, Perceptive Advisors, Vivo Capital, Vestal Point Capital, What If Ventures and 24 more.
Who are Alto Neuroscience's competitors?
Competitors of Alto Neuroscience include Senseye and 5 more.
Loading...
Compare Alto Neuroscience to Competitors
nQ Medical operates as a neurotechnology company. It specializes in digital biomarker development to accelerate research, advance disease detection, and improve care. The company was founded in 2016 and is based in Cambridge, Massachusetts.
BrainCheck focuses on cognitive health and operates in the healthcare technology sector. The company offers a digital platform that provides cognitive assessments, clinical decision support, and cognitive care planning. Its services are designed to help healthcare providers identify and manage dementia and cognitive impairment in their patients. It was founded in 2015 and is based in Austin, Texas.
Earable Neuroscience specializes in sleep technology, focusing on the development of AI-powered wearables within the wellness sector. The company's main offering, the FRENZ Brainband, is a wearable device that tracks and stimulates brain activities to enhance sleep, utilizing bone-conduction speakers to deliver audio sessions based on data analysis. The FRENZ Brainband provides features such as sleep scoring, audio content adaptation, and a smart alarm that aligns with the user's sleep cycle. It was founded in 2018 and is based in Boulder, Colorado.
Biotrial is a Contract Research Organization (CRO) that specializes in drug development within the pharmaceutical and biotech industries. The company offers a wide range of services including preclinical pharmacology, clinical development, bioanalysis, biometrics, and medical imaging. Biotrial primarily serves the pharmaceutical and biotech industries. It was founded in 1989 and is based in Rennes, France.
Myelin-H focuses on the remote monitoring and management of brain diseases within the healthcare technology sector. The company offers a platform that facilitates the tracking and analysis of patient data for brain conditions. This technology serves as a tool for healthcare professionals to manage disease progression remotely. It was founded in 2021 and is based in London, United Kingdom.
Biomind Labs is a biotech research and development company operating in the pharmaceutical industry. The company focuses on developing novel pharmaceutical drugs and innovative nanotech delivery systems for treating various psychiatric and neurological conditions. These products are designed to transform biomedical sciences knowledge into fast-acting and controlled-release drugs that target specific therapeutic indications. It is based in Toronto, Ontario.
Loading...